Literature DB >> 9647741

Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin.

A Mizuno1, N Amizuka, K Irie, A Murakami, N Fujise, T Kanno, Y Sato, N Nakagawa, H Yasuda, S Mochizuki, T Gomibuchi, K Yano, N Shima, N Washida, E Tsuda, T Morinaga, K Higashio, H Ozawa.   

Abstract

Osteoclasts are multinucleated cells that resorb bone. Osteoclastogenesis inhibitory factor (OCIF), also called osteoprotegerin (OPG), acts as a naturally occurring decoy receptor for osteoclast differentiation factor, which mediates an essential signal to osteoclast progenitors for their differentiation into osteoclasts. Here we show that the OCIF/OPG knockout mice exhibited severe osteoporosis due to enhanced osteoclastogenesis when they grew to be adults. These mice were viable and fertile. They exhibited marked bone loss accompanied by destruction of growth plate and lack of trabecular bone in their femurs. The strength of their bones dramatically decreased. These results demonstrate that OCIF/OPG is a key factor acting as a negative regulator against osteoclastogenesis. The OCIF/OPG knockout mice provide the first animal model for osteoporosis without other obvious abnormalities.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9647741     DOI: 10.1006/bbrc.1998.8697

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  165 in total

Review 1.  Osteoprotegerin.

Authors:  U Feige
Journal:  Ann Rheum Dis       Date:  2001-11       Impact factor: 19.103

2.  Combination therapy with BMP-2 and a systemic RANKL inhibitor enhances bone healing in a mouse critical-sized femoral defect.

Authors:  Sofia Bougioukli; Ashish Jain; Osamu Sugiyama; Brian A Tinsley; Amy H Tang; Matthew H Tan; Douglas J Adams; Paul J Kostenuik; Jay R Lieberman
Journal:  Bone       Date:  2015-12-23       Impact factor: 4.398

3.  Osteoprotegerin (OPG) and receptor activator of NF-kB ligand (RANK-L) serum levels in patients on chronic hemodialysis.

Authors:  S Gonnelli; A Montagnani; C Caffarelli; A Cadirni; M S Campagna; M B Franci; B Lucani; E Gaggiotti; R Nuti
Journal:  J Endocrinol Invest       Date:  2005-06       Impact factor: 4.256

4.  Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours.

Authors:  C Van Poznak; S S Cross; M Saggese; C Hudis; K S Panageas; L Norton; R E Coleman; I Holen
Journal:  J Clin Pathol       Date:  2006-01       Impact factor: 3.411

5.  Gamma interferon positively modulates Actinobacillus actinomycetemcomitans-specific RANKL+ CD4+ Th-cell-mediated alveolar bone destruction in vivo.

Authors:  Yen-Tung A Teng; Deeqa Mahamed; Bhagirath Singh
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

6.  RANKL employs distinct binding modes to engage RANK and the osteoprotegerin decoy receptor.

Authors:  Christopher A Nelson; Julia T Warren; Michael W-H Wang; Steven L Teitelbaum; Daved H Fremont
Journal:  Structure       Date:  2012-10-02       Impact factor: 5.006

Review 7.  Recent advances in osteoclast biology.

Authors:  Takehito Ono; Tomoki Nakashima
Journal:  Histochem Cell Biol       Date:  2018-02-01       Impact factor: 4.304

Review 8.  Inflammatory osteolysis: a conspiracy against bone.

Authors:  Gabriel Mbalaviele; Deborah V Novack; Georg Schett; Steven L Teitelbaum
Journal:  J Clin Invest       Date:  2017-06-01       Impact factor: 14.808

9.  Osteocalcin positive mononuclear cells are associated with the severity of aortic calcification.

Authors:  Shripad N Pal; Catherine Rush; Adam Parr; Ann Van Campenhout; Jonathan Golledge
Journal:  Atherosclerosis       Date:  2009-11-10       Impact factor: 5.162

Review 10.  Gene expression studies of osteoporosis: implications for microarray research.

Authors:  V Dvornyk; R R Recker; H-W Deng
Journal:  Osteoporos Int       Date:  2003-04-29       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.